Home Biosimilar Antibodies Neuronal Signaling MAO Simtuzumab (Anti-LOXL2)
For research use only. Not for use in humans.

Simtuzumab (Anti-LOXL2)

Synonyms: AB 0024, GS 6624

Simtuzumab (Anti-LOXL2) is a monoclonal antibody directed against Lysyl oxidase like-2 (LOXL2) with potential antineoplastic activity. MW: 145.5 kD.

Simtuzumab (Anti-LOXL2)

1 Citation

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: A240801 Purity: 99% Protein concentration: 11.22mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation MAO-A MAO-B MAO Others
Moclobemide (Ro 111163) 6
Vafidemstat 0 LSD1/KDM1A
Norharmane 1
MAO-B-IN-2 0 BChE
Xanthoangelol 1 dopamine-beta-hydroxylase
4-Hydroxyderricin 0
Toloxatone (MD69276) 0
TB5 0
Lazabemide 0
Harmine 5 PPARγ
Isatin 2
Sennoside A 2
Paeonol 2
Glycyrrhizin (Glycyrrhizic Acid, NSC 167409) 44 HMGB1,11 beta-hydroxysteroid dehydrogenase
Harmane 0
Iproniazid phosphate 0
Myristicin 0 CYP1A2
Hypericin 1 P450,Telomerase,Reverse transcriptase
Eprobemide 0
Iproniazid 0
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Simtuzumab (Anti-LOXL2) is a monoclonal antibody directed against Lysyl oxidase like-2 (LOXL2) with potential antineoplastic activity. MW: 145.5 kD.

Product Details

CAS No. 1318075-13-6
Molecular Weight 145.5 kDa
Isotype Human IgG4SP
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02466516 COMPLETED Drug: SEL Non-Alcoholic Steatohepatitis (NASH) Gilead Sciences 2015-06-08 PHASE2
NCT01672853 COMPLETED Primary Sclerosing Cholangitis (PSC) Gilead Sciences 2013-03-04 PHASE2
NCT01769196 TERMINATED Drug: Simtuzumab|Drug: Simtuzumab placebo Idiopathic Pulmonary Fibrosis Gilead Sciences 2013-01-31 PHASE2
NCT01759511 TERMINATED Drug: Simtuzumab Idiopathic Pulmonary Fibrosis Gilead Sciences 2012-10-18 PHASE2
NCT01707472 COMPLETED Liver Fibrosis; Hepatitis C; HIV; HIV/HCV Co-infection Gilead Sciences 2012-10-04 PHASE2
NCT01479465 TERMINATED Drug: Placebo to match SIM|Drug: Leucovorin|Drug: Irinotecan Colorectal Cancer Gilead Sciences 2011-12 PHASE2

(data from https://clinicaltrials.gov, updated on 2019-06-26)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.